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1. Introduction 
Nafazatrom has been reported to possess significant 
antithrombotic and thrombolytic activity in model 
systems of experimental thrombosis [ 11. The mecha- 
nism of action for these antithrombotic effects 
appears related to the ability of the drug to stimulate 
prostacyclin (PG12) production by the vascular wall 
[2]. Nafazatrom has been reported to possess signifi- 
cant antimetastatic a tivity [3] presumably due to 
its ability to enhance PGIZ production, as PGIz itself 
is a potent antimetastatic agent [4]. Considering the 
effect of nafazatrom on arachidonic acid metabolism 
[ 51 and the suspected importance of these metabolites 
in tumor growth [6] we examined the effects of 
nafazatrom on tumor cell proliferation in vitro and 
in vivo and on tumor cell arachidonic acid metabolism. 
We report here that nafazatrom inhibits tumor cell 
lipoxygenase activity but not prostaglandin endo- 
peroxide synthetase (cyclooxygenase t hydroperoxi- 
dase). Further, this compound was found to be a 
potent cytostatic agent against the B16 amelanotic’ 
melanoma (B16a). 
Viabilities were determined by vital dye exclusion 
and lactate dehydrogenase (LDH) release as deter- 
mined fluorometrically [9]. 
For DNA, RNA or protein synthesis experiments 
the tumor cells were further purified by centrifugal 
elutriation as in [7]. [3H]Thymidine (New England 
Nuclear, 80 Ci/mmol) incorporation into acid-insolu- 
ble DNA, t3H]uridine (New England Nuclear, 56 Ci/ 
mmol) incorporation into acid-insoluble RNA, and 
[3H]leucine (New England Nuclear, 39 Ci/mmol) 
incorporation into protein were determined asin [ 101. 
2. Materials and methods 
The B16a was propagated by subcutaneous implan- 
tation in male syngeneic C57BL/6J mice (Jackson 
Lab., l$r Harbor ME). Tumors (OS-l.5 g) were 
removed and disaggregated to yield monodispersed 
cells [7]. Freshly dispersed B16a tumor cells were 
adapted for growth in tissue culture medium [8] 
allowed to grow to confluency in primary culture 
then subcultured one time for use in these experi- 
ments. The cells were counted in a hemocytometer. 
Arachidonic acid metabolism was measured in the 
microsomal pellet (indomethacin-sensitive cyclo- 
oxygenase activity) and microsomal supernatant 
(lipoxygenase activity) from B16a tumors. Tumors 
were homogenized in 250 mM d-mannitol, 1mM 
EDTA and 0.4% fatty acid free bovine serum albumin 
in 100 mM phosphate buffer (PH 7.8) (PBS). The 
supernatant from 2 centrifugations (8500 X g, 10 min) 
was recentrifuged at 100 000 X g for 45 min. The 
pellets were resuspended in PBS and 3 mg palmitic 
acid was added to each 5 ml supematant. Pellet or 
supematant (1 ml) was preincubated with the drugs 
for 5 min at 37°C in a shaking water bath. Then 
5 nmol hematin, 5 nmol epinephrine and 1.9 nmol 
[ 14C] arachidonic acid were incubated for 15 min at 
37°C. The assays were terminated by lowering the 
pH to 3.5 with 1 N HCI. Samples were extracted in 
ethyl acetate and dried under Nz and then chromato- 
graphed by TLC in hexanediethyl ether:acetic acid 
(50:50: 1). TLC plates were scanned with a Berthold 
radiochromatogram scanner. 
Nafazatrom (Bay g 6757; l- [(2j$napthyloxy)ethyl]- 
3-methyl-2-pyrazolin-5ane; fig.1) was dissolved in 
0.1 N NaOH and diluted in culture medium or 0.9% 
NaCl to final concentrations. 
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Fig.1. Chemical structure of nafazatrom. 
3. Results 
The effects of nafazatrom on proliferation of B16a 
cells in culture were examined over a period of 
14 days. Media was changed and drug added every 
other day. A dose-dependent decrease incell prolifera- 
tion was observed with a minimal effective dose of 
0.1 pg/ml (fig.2). This effect of nafazatrom was not 
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Fig.2. Effects of nafazatrom on proliferation of B16a cells 
in culture. The numbers above each bar represent fmal cell 
viabilities determined by vital dye exclusion. Similarly, there 
was no difference in LDH release between controls and 
nafazatrom-treated cells (not shown). Values are expressed 
asx*SEM;n=S. 
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Fig.3. Dosedependent inhibition of DNA synthesis (IsHI- 
thymidine incorporation) by B16a cells following exposure 
to nafazatrom. n = 4. 
due to cytotoxicity as determined by vital dye exclu- 
sion and LDH release (fig.2). Nafazatrom also 
decreased [ 3H] thymidine incorporation into DNA. 
Exposure of B16a tumor cells to nafazatrom for 4 h 
produced a dose-dependent decrease in DNA synthe- 
sis with an EDso of 0.6 pg/mI (fig.3). After a 4 h 
exposure to nafazatrom, RNA synthesis was inhibited 
in parallel with inhibition of DNA synthesis. Protein 
synthesis was unaffected at this time interval (fig.4). 
In a preliminary in vivo experiment animals were 
injected subcutaneously with 10’ B16a tumor cells 
and treated with Nafazatrom (SC) at 0.8 mg/kg for 
21 days. Final tumor weight in treated animals 
(0.49 + 0.27 g; n = 12) was significantly decreased 
from untreated controls (3.98 * 0.39 g; n = 12). 
Nafazatrom inhibited the formation of monohy- 
droxy fatty acids synthesized from the lipoxygenase 
pathway by B16a cells (fig.5, EDso = 3 PM). This 
816 amelmlii mehm 
Fig.4. Effects of nafazatrom on protein ([‘H]leucine), RNA 
([‘Hluridine) and DNA ([‘Hlthymidine) synthesis by B16a 
cells: x f SEM;n = 4. 
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The effectiveness of this compound both in vivo and 
in vitro at low doses uggests its potential as a cancer 
chemotherapeutic agent. Nafazatrom unlike current 
chemotherapeutic agents [111 does not appear to be 
a cytotoxic agent at its effective dose(s). In animal 
models nafazatrom is not toxic at 10 g/kg acute 
exposure [1 ] and no toxicity has been reported fol- 
lowing administration tohuman volunteers [2]. 
The mechanism by which nafazatrom inhibits 
tumor cell proliferation is unclear, However, we have 
observed that nafazatrom behaves as a lipoxygenase 
inhibitor and therefore would inhibit the conver- 
sion of arachidonic acid to hydroperoxyeicosatet- 
raenoic acid isomers (5-,8-,9-,11 -,12- and 15HPETEs) 
It has been observed that the B16a melanoma (this 
study) and the Lewis lung carcinoma (unpublished) 
produce at least 2 lipoxygenase products (5HPETE 
and 12HPETE). These hydroperoxy fatty acids have 
been demonstrated to increase cellular cGMP [ 12- 
14], a compound which has been described as a posi- 
tive signal for cellular proliferation [15,161. We 
speculate that the ability of nafazatrom to inhibit 
tumor cell proliferation and tumor growth may be 
related to its activity as a lipoxygenase inhibitor. 
SO,& lndomethacin 
Fig.5. Radiochromatogram scans of [ ?]arachidonic acid 
(20:4) conversion into monohydroxy fatty acids by the 
microsomal supernatant from B16a tumor cells. Boiled super- 
natant scan indicates that this conversion was enzymatic. 
ETYA and nafazatrom inhibited conversion of 20:4 into 
monohydroxy fatty acids but indomethacin did not. 
product was not inhibited by indomethacin (50 w), 
a cyclooxygenase inhibitor, but was inhibited by 
5,8,11,14eicosatetraynoic acid (ETYA;EDse = 0.9 PM), 
an inhibitor of both the lipoxygenase and cyclo- 
oxygenase pathways. Subsequent analysis resolved 
the monohydroxy fatty acid peak shown in fig.5 into 
2 components one of which corn&rated with authen- 
tic 5hydroxyeicosatetraenoic acid (5-HETE), a 
metabolite of 5-hydroperoxyeicosatetraenoic acid
OHPETE) and the second comigrated with authentic 
12-hydroxyeicosatetraenoic ac d(12-HETE), a metab- 
olite of 12.hydroperoxyeicosatetraenoic acid (12. 
HPETE) (not shown). Nafazatrom at the doses 
studied did not inhibit formation of cyclooxygenase 
products. 
4. Discussion 
Nafazatrom demonstrated inhibition of tumor 
cell proliferation in vitro and tumor growth in vivo. 
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